{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:47:40Z","timestamp":1794635260697,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with chronic hepatitis B (CHB) commonly experience social and self-stigma. This study sought to understand the impacts of CHB-related stigma and a functional cure on stigma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with CHB with a wide range of age and education were recruited from 5 countries and participated in 90-minute qualitative, semi-structured interviews to explore concepts related to CHB-associated stigma and its impact. Participants answered open-ended concept-elicitation questions regarding their experience of social and self-stigma, and the potential impact of reduced CHB-related stigma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-three participants aged 25 to 71 years (15 from the United States and 12 each from China, Germany, Italy, and Japan) reported emotional, lifestyle, and social impacts of living with CHB, including prejudice, marginalization, and negative relationship and work experiences. Self-stigma led to low self-esteem, concealment of CHB status, and social withdrawal. Most participants stated a functional cure for hepatitis B would reduce self-stigma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CHB-related social and self-stigma are widely prevalent and affect many aspects of life. A functional cure for hepatitis B may reduce social and self-stigma and substantially improve the health-related quality of life of people with CHB. Incorporating stigma into guidelines along with infectivity considerations may broaden the patient groups who should receive treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-023-17263-6","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T06:02:33Z","timestamp":1708927353000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States"],"prefix":"10.1186","volume":"24","author":[{"given":"Mondher","family":"Toumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chari","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Macey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Slagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"van B\u00f6mmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Habuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano","family":"Sbarigia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Beumont-Mauviel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina Villasis","family":"Keever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Radunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Puggina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Hilgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"17263_CR1","unstructured":"World Health Organization, Hepatitis B. 2021. https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed 20 Jul 2022."},{"issue":"6","key":"17263_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"The Polaris Observatory Collaborators","year":"2018","unstructured":"The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus Infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"30","key":"17263_CR3","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.4254\/wjh.v7.i30.2955","volume":"7","author":"N Coppola","year":"2015","unstructured":"Coppola N, Alessio L, Pisaturo M, Macera M, Sagnelli C, Zampino R, et al. Hepatitis B virus Infection in immigrant populations. World J Hepatol. 2015;7(30):2955\u201361.","journal-title":"World J Hepatol"},{"key":"17263_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/PROM.S226936","volume":"11","author":"J Smith-Palmer","year":"2020","unstructured":"Smith-Palmer J, Cerri K, Sbarigia U, Chan EKH, Pollock RF, Valentine WJ, et al. Impact of stigma on people living with chronic hepatitis B. Patient Relat Outcome Meas. 2020;11:95\u2013107.","journal-title":"Patient Relat Outcome Meas"},{"issue":"1 Suppl","key":"17263_CR5","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1177\/0033354920921252","volume":"135","author":"K Moraras","year":"2020","unstructured":"Moraras K, Block J, Shiroma N, Cannizzo A, Cohen C. Protecting the rights of health care students living with hepatitis B under the americans with disabilities act. Public Health Rep. 2020;135(1 Suppl):13S\u201318S.","journal-title":"Public Health Rep"},{"key":"17263_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.12688\/wellcomeopenres.14273.1","volume":"3","author":"J Mokaya","year":"2018","unstructured":"Mokaya J, McNaughton AL, Burbridge L, Maponga T, O\u2019Hara G, Andersson M, et al. A blind spot? Confronting the stigma of hepatitis B virus (HBV) Infection - a systematic review. Wellcome Open Res. 2018;3:29.","journal-title":"Wellcome Open Res"},{"issue":"4","key":"17263_CR7","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/hep.30899","volume":"71","author":"K McCulloch","year":"2020","unstructured":"McCulloch K, Romero N, MacLachlan J, Allard N, Cowie B. Modeling progress toward elimination of hepatitis B in Australia. Hepatology. 2020;71(4):1170\u201381.","journal-title":"Hepatology"},{"key":"17263_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-4-45","volume":"4","author":"J Wallace","year":"2011","unstructured":"Wallace J, McNally S, Richmond J, Hajarizadeh B, Pitts M. Managing chronic Hepatitis B: a qualitative study exploring the perspectives of people living with chronic hepatitis B in Australia. BMC Res Notes. 2011;4: 45.","journal-title":"BMC Res Notes"},{"issue":"8","key":"17263_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/070674371205700804","volume":"57","author":"PW Corrigan","year":"2012","unstructured":"Corrigan PW, Rao D. On the self-stigma of mental illness: stages, disclosure, and strategies for change. Can J Psychiatry. 2012;57(8):464\u20139.","journal-title":"Can J Psychiatry"},{"key":"17263_CR10","unstructured":"Hepatitis B Foundation. The voice of the patient: living with chronic hepatitis B. Report of an externally-led patient-focused drug development meeting. 2020. https:\/\/www.hepb.org\/assets\/Uploads\/ExPFDD-Report-HBF-10-1-2020.pdf. Accessed 20 Jul 2022."},{"key":"17263_CR11","doi-asserted-by":"crossref","unstructured":"Jin D, Treloar C, Brener L. Hepatitis B virus related stigma among Chinese living in mainland China: a scoping review. Psychol Health Med.\u00a02022;27(8):1760\u201373.","DOI":"10.1080\/13548506.2021.1944651"},{"issue":"7903","key":"17263_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/d41586-022-00816-x","volume":"603","author":"C Ainsworth","year":"2022","unstructured":"Ainsworth C. Destigmatizing hepatitis B. Nature. 2022;603(7903):54\u20136.","journal-title":"Nature"},{"issue":"11","key":"17263_CR13","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1111\/liv.13168","volume":"36","author":"J Huang","year":"2016","unstructured":"Huang J, Guan ML, Balch J, Wu E, Rao H, Lin A, et al. Survey of hepatitis B knowledge and stigma among chronically infected patients and uninfected persons in Beijing, China. Liver Int. 2016;36(11):1595\u2013603.","journal-title":"Liver Int"},{"issue":"1","key":"17263_CR14","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1186\/s12889-021-11093-0","volume":"21","author":"C Freeland","year":"2021","unstructured":"Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, et al. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health. 2021;21(1):1004.","journal-title":"BMC Public Health"},{"issue":"4","key":"17263_CR15","doi-asserted-by":"publisher","first-page":"e0195455","DOI":"10.1371\/journal.pone.0195455","volume":"13","author":"B Han","year":"2018","unstructured":"Han B, Yuan Q, Shi Y, Wei L, Hou J, Shang J, et al. The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China. PLoS One. 2018;13(4):e0195455.","journal-title":"PLoS One"},{"issue":"1","key":"17263_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12939-017-0637-4","volume":"16","author":"J Wallace","year":"2017","unstructured":"Wallace J, Pitts M, Liu C, Lin V, Hajarizadeh B, Richmond J, et al. More than a virus: a qualitative study of the social implications of hepatitis B infection in China. Int J Equity Health. 2017;16(1):137.","journal-title":"Int J Equity Health"},{"issue":"5","key":"17263_CR17","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/v12050515","volume":"12","author":"T Tu","year":"2020","unstructured":"Tu T, Block JM, Wang S, Cohen C, Douglas MW. The lived experience of chronic hepatitis B: a broader view of its impacts and why we need a cure. Viruses. 2020;12(5):515.","journal-title":"Viruses"},{"issue":"2","key":"17263_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1037\/a0031889","volume":"60","author":"DL Vogel","year":"2013","unstructured":"Vogel DL, Bitman RL, Hammer JH, Wade NG. Is stigma internalized? The longitudinal impact of public stigma on self-stigma. J Couns Psychol. 2013;60(2):311\u20136.","journal-title":"J Couns Psychol"},{"issue":"3","key":"17263_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.appsy.2005.07.001","volume":"11","author":"PW Corrigan","year":"2005","unstructured":"Corrigan PW, Kerr A, Knudsen L. The stigma of mental illness: explanatory models and methods for change. Appl Prev Psychol. 2005;11(3):179\u201390.","journal-title":"Appl Prev Psychol"},{"issue":"2","key":"17263_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/SGA.0000000000000223","volume":"40","author":"L Valizadeh","year":"2017","unstructured":"Valizadeh L, Zamanzadeh V, Bayani M, Zabihi A. The social stigma experience in patients with hepatitis B infection: a qualitative study. Gastroenterol Nurs. 2017;40(2):143\u201350.","journal-title":"Gastroenterol Nurs"},{"issue":"3","key":"17263_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/ijerph16030398","volume":"16","author":"TV Le","year":"2019","unstructured":"Le TV, Vu TTM, Mai HT, Nguyen LH, Truong NT, Hoang CL, et al. Social determinants of stigma and discrimination in Vietnamese patients with chronic hepatitis B. Int J Environ Res Public Health. 2019;16(3):398.","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"17263_CR22","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/liv.13189","volume":"36","author":"K Liu","year":"2016","unstructured":"Liu K. Hepatitis B infection in China: the stigma behind the stigmata. Liver Int. 2016;36(11):1582\u20134.","journal-title":"Liver Int"},{"issue":"9","key":"17263_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1155\/2012\/705094","volume":"26","author":"D Li","year":"2012","unstructured":"Li D, Tang T, Patterson M, Ho M, Heathcote J, Shah H. The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons. Can J Gastroenterol. 2012;26(9):597\u2013602.","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"17263_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1071\/SH10137","volume":"9","author":"J Wallace","year":"2012","unstructured":"Wallace J, McNally S, Richmond J, Hajarizadeh B, Pitts M. Challenges to the effective delivery of health care to people with chronic hepatitis B in Australia. Sex Health. 2012;9(2):131\u20137.","journal-title":"Sex Health"},{"key":"17263_CR25","unstructured":"World Hepatitis Alliance. Holding governments accountable. World Hepatitis Alliance Civil Society Survey: global findings report. 2017. https:\/\/www.worldhepatitisalliance.org\/wp-content\/uploads\/2017\/10\/holding_governments_accountable_-_civil_society_survey_report.pdf. Accessed 20 Jul 2022."},{"issue":"1","key":"17263_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"issue":"4","key":"17263_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/hep.29323","volume":"66","author":"AS Lok","year":"2017","unstructured":"Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: from discovery to regulatory approval. Hepatology. 2017;66(4):1296\u2013313.","journal-title":"Hepatology"},{"key":"17263_CR28","unstructured":"US Food & Drug Administration. Plan for issuance of patient-focused drug development guidance under 21st Century Cures Act Title III Section 3002. 2017. https:\/\/www.fda.gov\/files\/about%20fda\/published\/Plan-for-Issuance-of-Patient%E2%80%90Focused-Drug-Development-Guidance.pdf. Accessed 20 Jul 2022."},{"issue":"8","key":"17263_CR29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research practices Task Force report: part 2\u2014assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"2","key":"17263_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qualitative Res Psychol"},{"key":"17263_CR31","doi-asserted-by":"publisher","DOI":"10.4135\/9781483384436","volume-title":"Applied thematic analysis","author":"G Guest","year":"2012","unstructured":"Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Thousand Oaks: Sage; 2012."},{"issue":"9","key":"17263_CR32","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):1408\u201316.","journal-title":"Qual Rep"},{"issue":"5","key":"17263_CR33","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/hep4.1875","volume":"6","author":"HSJ Choi","year":"2022","unstructured":"Choi HSJ, Tonthat A, Janssen HLA, Terrault NA. Aiming for functional cure with established and novel therapies for chronic hepatitis B. Hepatol Commun. 2022;6(5):935\u201349.","journal-title":"Hepatol Commun"},{"key":"17263_CR34","unstructured":"Wallace J, Pitts M, Liu C, Lin V, Wei L, Hajarizadeh B, et al. Needs assessment of people with viral hepatitis \u2013 China. 2015. https:\/\/www.researchgate.net\/profile\/Jack-Wallace-3\/publication\/280721610_Needs_assessment_of_people_with_viral_hepatitis_China\/links\/55c2bc5008aebc967defe1d6\/Needs-assessment-of-people-with-viral-hepatitis-China.pdf. Accessed 20 Jul 2022."},{"issue":"9","key":"17263_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.31128\/AJGP-02-20-5225","volume":"49","author":"J Wallace","year":"2020","unstructured":"Wallace J, Richmond J, Allard N, Howell J, Adamson E, Xiao Y, et al. Facilitating hepatitis B clinical management in general practice: a qualitative investigation. Aust J Gen Pract. 2020;49(9):599\u2013604.","journal-title":"Aust J Gen Pract"},{"issue":"3","key":"17263_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1539\/joh.15-0288-OA","volume":"58","author":"T Ishimaru","year":"2016","unstructured":"Ishimaru T, Wada K, Arphorn S, Smith DR. Barriers to the acceptance of work colleagues infected with hepatitis B and hepatitis C in Japan. J Occup Health. 2016;58(3):269\u201375.","journal-title":"J Occup Health"},{"issue":"9","key":"17263_CR37","doi-asserted-by":"publisher","first-page":"e76921","DOI":"10.1371\/journal.pone.0076921","volume":"8","author":"H Eguchi","year":"2013","unstructured":"Eguchi H, Wada K. Knowledge of HBV and HCV and individuals\u2019 attitudes toward HBV- and HCV-infected colleagues: a national cross-sectional study among a working population in Japan. PLoS One. 2013;8(9):e76921.","journal-title":"PLoS One"},{"issue":"11","key":"17263_CR38","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1111\/jvh.13592","volume":"28","author":"C Freeland","year":"2021","unstructured":"Freeland C, Racho R, Kamischke M, Moraras K, Wang E, Cohen C. Cure everyone and vaccinate the rest: the patient perspective on future hepatitis B treatment. J Viral Hepat. 2021;28(11):1539\u201344.","journal-title":"J Viral Hepat"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-17263-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-17263-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-17263-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T06:04:18Z","timestamp":1708927458000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-17263-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["17263"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-17263-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki. The study protocol was reviewed and approved by relevant institutional ethics review boards (United States, Western Independent Review Board [WIRB]; Germany, Western Independent Review Board [WIRB]; Italy, Western Independent Review Board [WIRB]; China, Shanghai Ethics Committee for Clinical Research; Japan, NPO MINS Ethics Review Committee). All participants completed an informed consent form before being interviewed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MT, JW, QN, DL, and YL have no disclosures. CC is the Senior Vice President at the Hepatitis B Foundation. The Hepatitis B Foundation receives unrestricted education and public health grants from Gilead Sciences, Janssen, GSK, Bristol Myers Squibb, Antios Therapeutics, VBI Vaccines, and Dynavax Technologies. HK, JM, HCP, and CM are employees of and stockholders of Clarivate; providing specialized clinical outcomes assessment and patient-centered outcomes consultancy to various pharmaceutical companies, including Janssen Global Services, LLC, which funded the conduct of this study. AFS consults with various pharmaceutical companies, including Janssen Global Services, LLC, which funded the conduct of this study. RGG has had grants\/research support from Gilead; is\/has been a consultant and\/or advisor to Abbott, AbbVie, Access Biologicals, Alexion, Antios, Arrowhead, Bayer AG, Bristol Myers Squibb, Eiger, Eisai, Enyo, eStudySite, Forty-Seven Inc, Gilead Sciences, HepaTx, HepQuant, Intercept, Ionis Pharmaceuticals, Janssen, Laboratory for Advanced Medicine, Lilly, Merck, Salix, Shionogi, Trimaran and Viking Therapeutics; provides consulting for ADMA Biologics, AEC Partners, Arena Pharmaceuticals Inc, Arterys Inc, Cirina, Consumer Health Products Association, DRG Abacus, Intellia, IQVIA, Kannalife, Labyrinth Holdings, Organovo, Patient Connect and Spring Bank; is on scientific or clinical advisory boards for Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, Hatch Biofund, HepQuant, Intercept, Janssen, and Medimmune; is an advisory consultant for Biocollections, Fujifilm\/Wako, and Quest; is on the data safety monitoring board for Ionis and Eiger; has speaker contracts with AbbVie, Bayer, Bristol Myers Squibb, Dova Pharmaceuticals, Eisai, Gilead, Intercept, Salix, and Shionogi; is a minor stock shareholder in Athenex, Triact, Riboscience, and Cocrystal; and has stock options in Athenex, Eiger, and HepQuant. Over 80% of the income from pharmaceutical companies received by RGG is directed to research, education, public policy, and\/or donated to charities. HY has a research grant provided by Chugai. MC has received lecture and consultant fees from Bristol Myers Squibb, Gilead, Roche Pharma, and Roche Diagnostics, and grant support from Roche Pharma and Roche Diagnostics. MB has been a member of speakers\u2019 bureaus for Bristol Myers Squibb, Gilead, Roche, and Janssen; and has been a member of advisory boards for AbbVie, Roche, Gilead and MSD. FvB consults for, is on the speakers\u2019 bureau for, and received grants from Gilead, Bristol Myers Squibb, and Roche, and has scientific collaboration with Roche and Janssen. QX reports payments from Roche, Bristol Myers Squibb, Novartis, and MSD. US, MB-M, AVK, YT, AL, QC, TI, OR, and EKHC are employees of Janssen Pharmaceutica and may hold stock in Johnson and Johnson. NH was an employee of Janssen Pharmaceuticals, but did not hold any stock in Johnson and Johnson, at the time of the study. AP was an employee of Janssen Pharmaceuticals at the time of the study and may hold stock in Johnson and Johnson. GH has received honoraria from Gilead for an educational event; payment from AbbVie for excellence training; and holds stock options in Johnson and Johnson. SW reports a FOCUS grant from Gilead Sciences outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"611"}}